PTK2 and melanoma: BRAFi-resistant melanoma cell lines displayed high active FAK levels [83], while a short-term (from 24 to 48 h) BRAFi treatment activated FAK in melanoma cells [39,47], which allowed for persistence under therapy through the acquisition of an NCSC phenotype [39].